Metabonomic profiling of TASTPM transgenic Alzheimer's disease mouse model

Journal of Proteome Research

Volumn 11, Issue 12, 2012, Pages 5903-5913

  Hu, Ze Ping ^a,c   Browne, Edward R ^b   Liu, Tao ^c   Angel, Thomas E ^c   Ho, Paul C ^a   Chan, Eric Chun Yong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GLAXOSMITHKLINE   (China)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

Alzheimer's disease; biomarker; GC MS; metabolic pathway; metabolic profiling; metabonomics; pathogenesis

Indexed keywords

ANDROSTENEDIONE; ARACHIDONIC ACID; FRUCTOSE; GALACTOSE; GLUCONIC ACID; GLUCOSE; HYDROCORTISONE; ISOLEUCINE; LEUCINE; LINOLEIC ACID; PALMITIC ACID; PENTOSE PHOSPHATE; PROGESTERONE; SERINE; SPHINGOLIPID; TESTOSTERONE; THREONINE; VALINE; ZYMOSTEROL;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BRAIN METABOLISM; CONTROLLED STUDY; ENERGY METABOLISM; FEMALE; GAS CHROMATOGRAPHY; LIPID METABOLISM; MALE; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMINO ACIDS; ANIMALS; BIOLOGICAL MARKERS; BRAIN; CARBOHYDRATE METABOLISM; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCONATES; GLUCOSE; HYDROCORTISONE; IMMUNOENZYME TECHNIQUES; LINOLEIC ACID; MALE; METABOLOME; METABOLOMICS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROGESTERONE;

MUS;

EID: 84870890908     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300666p     Document Type: Article

References (84)

1. Braak, H.; Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories Neurobiol. Aging 1997, 18 (4) 351-7
2. Pericak-Vance, M. A.; Bass, M. P.; Yamaoka, L. H.; Gaskell, P. C.; Scott, W. K.; Terwedow, H. A.; Menold, M. M.; Conneally, P. M.; Small, G. W.; Vance, J. M.; Saunders, A. M.; Roses, A. D.; Haines, J. L. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12 JAMA, J. Am. Med. Assoc. 1997, 278 (15) 1237-41
3. Rogaev, E. I.; Sherrington, R.; Wu, C.; Levesque, G.; Liang, Y.; Rogaeva, E. A.; Ikeda, M.; Holman, K.; Lin, C.; Lukiw, W. J.; de Jong, P. J.; Fraser, P. E.; Rommens, J. M., St; George-Hyslop, P. Analysis of the 5' sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease Genomics 1997, 40 (3) 415-24
4. Maes, O. C.; Xu, S.; Yu, B.; Chertkow, H. M.; Wang, E.; Schipper, H. M. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray Neurobiol. Aging 2007, 28 (12) 1795-809
5. Unger, T.; Korade, Z.; Lazarov, O.; Terrano, D.; Schor, N. F.; Sisodia, S. S.; Mirnics, K. Transcriptome differences between the frontal cortex and hippocampus of wild-type and humanized presenilin-1 transgenic mice Am. J. Geriatr. Psychiatry 2005, 13 (12) 1041-51
6. Zhang, J.; Montine, T. J. Proteomic discovery of CSF biomarkers for Alzheimer's disease Ann. Neurol. 2007, 61 (5) 497
7. Author reply 497-8.
8. Lovestone, S.; Guntert, A.; Hye, A.; Lynham, S.; Thambisetty, M.; Ward, M. Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers Expert Rev. Proteomics 2007, 4 (2) 227-38
9. Papassotiropoulos, A.; Fountoulakis, M.; Dunckley, T.; Stephan, D. A.; Reiman, E. M. Genetics, transcriptomics, and proteomics of Alzheimer's disease J. Clin. Psychiatry 2006, 67 (4) 652-70
10. Nicholson, J. K.; Lindon, J. C.; Holmes, E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data Xenobiotica 1999, 29 (11) 1181-9
11. Kaddurah-Daouk, R.; Kristal, B. S.; Weinshilboum, R. M. Metabolomics: A global biochemical approach to drug response and disease Annu. Rev. Pharmacol. Toxicol. 2008, 48, 653-83
12. Bogdanov, M.; Matson, W. R.; Wang, L.; Matson, T.; Saunders-Pullman, R.; Bressman, S. S.; Flint Beal, M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease Brain 2008, 131 (2) 389-96
13. Underwood, B. R.; Broadhurst, D.; Dunn, W. B.; Ellis, D. I.; Michell, A. W.; Vacher, C.; Mosedale, D. E.; Kell, D. B.; Barker, R. A.; Grainger, D. J.; Rubinsztein, D. C. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles Brain 2006, 129 (4) 877-86
14. Holmes, E.; Tsang, T. M.; Huang, J.T-H.; Markus Leweke, F.; Koethe, D.; Gerth, C. W.; Nolden, B. M.; Gross, S.; Schreiber, D.; Nicholson, J. K.; Bahn, S. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia PLoS Med. 2006, 3 (8) e327
15. 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease J. Biol. Chem. 2005, 280 (52) 42508-14
16. Dedeoglu, A.; Choi, J. K.; Cormier, K.; Kowall, N. W.; Jenkins, B. G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile Brain Res. 2004, 1012 (1-2) 60-5
17. von Kienlin, M.; Kunnecke, B.; Metzger, F.; Steiner, G.; Richards, J. G.; Ozmen, L.; Jacobsen, H.; Loetscher, H. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span Neurobiol. Dis. 2005, 18 (1) 32-9
18. Marjanska, M.; Curran, G. L.; Wengenack, T. M.; Henry, P.-G.; Bliss, R. L.; Poduslo, J. F.; Jack, C. R., Jr.; UgIurbil, K.; Garwood, M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (33) 11906-10
19. Jiang, N.; Yan, X.; Zhou, W.; Zhang, Q.; Chen, H.; Zhang, Y.; Zhang, X. NMR-based metabonomic investigations into the metabolic profile of the senescence-accelerated mouse J. Proteome Res. 2008, 7 (9) 3678-86
20. Tukiainen, T.; Tynkkynen, T.; Mäkinen, V. P.; Jylänki, P.; Kangas, A.; Hokkanen, J.; Vehtari, A.; Gröhn, O.; Hallikainen, M.; Soininen, H.; Kivipelto, M.; Groop, P. H.; Kaski, K.; Laatikainen, R.; Soininen, P.; Pirttilä, T.; Ala-Korpela, M. A multi-metabolite analysis of serum by (1)H NMR spectroscopy: Early systemic signs of Alzheimer's disease Biochem. Biophys. Res. Commun. 2008, 375 (3) 356-61
21. Greenberg, N.; Grassano, A.; Thambisetty, M.; Lovestone, S.; Legido-Quigley, C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease Electrophoresis 2009, 30 (7) 1235-9
22. Salek, R. M.; Xia, J.; Innes, A.; Sweatman, B. C.; Adalbert, R.; Randle, S.; McGowan, E.; Emson, P. C.; Griffin, J. L. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease Neurochem. Int. 2010, 56 (8) 937-47
23. Li, N. J.; Liu, W. T.; Li, W.; Li, S. Q.; Chen, X. H.; Bi, K. S.; He, P. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry Clin. Biochem. 2010, 43 (12) 992-7
24. Kaddurah-Daouk, R.; Rozen, S.; Matson, W.; Han, X.; Hulette, C. M.; Burke, J. R.; Doraiswamy, P. M.; Welsh-Bohmer, K. A. Metabolomic changes in autopsy-confirmed Alzheimer's disease Alzheimer's Dementia 2011, 7 (3) 309-17
25. Han, X.; Rozen, S.; Boyle, S. H.; Hellegers, C.; Cheng, H.; Burke, J. R.; Welsh-Bohmer, K. A.; Doraiswamy, P. M.; Kaddurah-Daouk, R. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics PLoS One 2011, 6 (7) e21643
26. Trushina, E.; Nemutlu, E.; Zhang, S.; Christensen, T.; Camp, J.; Mesa, J.; Siddiqui, A.; Tamura, Y.; Sesaki, H.; Wengenack, T. M.; Dzeja, P. P.; Poduslo, J. F. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease PLoS One 2012, 7 (2) e32737
27. Sato, Y.; Suzuki, I.; Nakamura, T.; Bernier, F.; Aoshima, K.; Oda, Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology J. Lipid Res. 2012, 53 (3) 567-76
28. Czech, C.; Berndt, P.; Busch, K.; Schmitz, O.; Wiemer, J.; Most, V.; Hampel, H.; Kastler, J.; Senn, H. Metabolite profiling of Alzheimer's disease cerebrospinal fluid PLoS One 2012, 7 (2) e31501
29. Shobab, L. A.; Hsiung, G. Y.; Feldman, H. H. Cholesterol in Alzheimer's disease Lancet Neurol. 2005, 4 (12) 841-52
30. Kivipelto, M.; Solomon, A. Cholesterol as a risk factor for Alzheimer's disease-epidemiological evidence Acta Neurol. Scand., Suppl. 2006, 185, 50-7
31. Bornemann, K. D.; Wiederhold, K. H.; Pauli, C.; Ermini, F.; Stalder, M.; Schnell, L.; Sommer, B.; Jucker, M.; Staufenbiel, M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice Am. J. Pathol. 2001, 158 (1) 63-73
32. Boncristiano, S.; Calhoun, M. E.; Kelly, P. H.; Pfeifer, M.; Bondolfi, L.; Stalder, M.; Phinney, A. L.; Abramowski, D.; Sturchler-Pierrat, C.; Enz, A.; Sommer, B.; Staufenbiel, M.; Jucker, M. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis J. Neurosci. 2002, 22 (8) 3234-43
33. van Dooren, T.; Dewachter, I.; Borghgraef, P.; van Leuven, F. Transgenic mouse models for APP processing and Alzheimer's disease: early and late defects Subcell. Biochem. 2005, 38, 45-63
34. Pugh, P. L.; Richardson, J. C.; Bate, S. T.; Upton, N.; Sunter, D. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease Behav. Brain Res. 2007, 178 (1) 18-28
35. Howlett, D. R.; Richardson, J. C.; Austin, A.; Parsons, A. A.; Bate, S. T.; Davies, D. C.; Gonzalez, M. I. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes Brain Res. 2004, 1017 (1-2) 130-6
36. Howlett, D. R.; Bowler, K.; Soden, P. E.; Riddell, D.; Davis, J. B.; Richardson, J. C.; Burbidge, S. A.; Gonzalez, M. I.; Irving, E. A.; Lawman, A.; Miglio, G.; Dawson, E. L.; Howlett, E. R.; Hussain, I. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease Histol. Histopathol. 2008, 23 (1) 67-76
37. Pardon, M. C.; Sarmad, S.; Rattray, I.; Bates, T. E.; Scullion, G. A.; Marsden, C. A.; Barrett, D. A.; Lowe, J.; Kendall, D. A. Repeated novel cage exposure-induced improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM mice is unrelated to changes in brain endocannabinoids levels Neurobiol. Aging 2007, 30 (7) 1099-113
38. Richardson, J. C.; Kendal, C. E.; Anderson, R.; Priest, F.; Gower, E.; Shoden, P.; Gray, R.; Topps, S.; Howlett, D. R.; Lavender, D.; Clarker, N. J.; Barnes, J. C.; Haworth, R.; Stewart, M. G.; Rupniak, H. T. R. Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease Neuroscience 2003, 122 (1) 213-28
39. Sankaranarayanan, S. Genetically modified mice models for Alzheimer's disease Curr. Top. Med. Chem. 2006, 6 (6) 609-27
40. Chui, D. H.; Tanahashi, H.; Ozawa, K.; Ikeda, S.; Checler, F.; Ueda, O.; Suzuki, H.; Araki, W.; Inoue, H.; Shirotani, K.; Takahashi, K.; Gallyas, F.; Tabira, T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation Nat. Med. 1999, 5 (5) 560-4
41. Holcomb, L.; Gordon, M. N.; McGowan, E.; Yu, X.; Benkovic, S.; Jantzen, P.; Wright, K.; Saad, I.; Mueller, R.; Morgan, D.; Sanders, S.; Zehr, C.; O'Campo, K.; Hardy, J.; Prada, C. M.; Eckman, C.; Younkin, S.; Hsiao, K.; Duff, K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes Nat. Med. 1998, 4 (1) 97-100
42. Culbert, A. A.; Skaper, S. D.; Howlett, D. R.; Evans, N. A.; Facci, L.; Soden, P. E.; Seymour, Z. M.; Guillot, F.; Gaestel, M.; Richardson, J. C. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease J. Biol. Chem. 2006, 281 (33) 23658-67
43. A, J.; Trygg, J.; Gullberg, J.; Johansson, A. I.; Jonsson, P.; Antti, H.; Marklund, S. L.; Moritz, T. Extraction and GC/MS analysis of the human blood plasma metabolome Anal. Chem. 2005, 77 (24) 8086-94
44. Denkert, C.; Budczies, J.; Kind, T.; Weichert, W.; Tablack, P.; Sehouli, J.; Silvia, N.; Könsgen, D.; Dietel, M.; Fiehn, O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors Cancer Res. 2006, 66 (22) 10795-804
45. Liere, P.; Akwa, Y.; Weill-Engerer, S.; Eychenne, B.; Pianos, A.; Robel, P.; Sjovall, J.; Schumacher, M.; Baulieu, E. E. Validation of an analytical procedure to measure trace amounts of neurosteroids in brain tissue by gas chromatography-mass spectrometry J. Chromatogr., B: Biomed. Sci. Appl. 2000, 739 (2) 301-12
46. Fekkes, D.; van der Cammen, T. J. M.; van Loon, C. P. M.; Verschoor, C.; van Harskamp, F.; de Koning, I.; Schudel, W. J.; Pepplinkhuizen, L. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia J. Neural Transm. 1998, 105 (2-3) 287-94
47. Haughey, N. J.; Bandaru, V. V.; Bae, M.; Mattson, M. P. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis Biochim. Biophys. Acta 2010, 1801 (8) 878-86
48. Prasad, M. R.; Lovell, M. A.; Yatin, M.; Dhillon, H.; Markesbery, W. R. Regional membrane phospholipid alterations in Alzheimer's disease Neurochem. Res. 1998, 23 (1) 81-8
49. Han, X.; M Holtzman, D.; McKeel, D. W., Jr.; Kelley, J.; Morris, J. C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis J. Neurochem. 2002, 82 (4) 809-18
50. He, X.; Huang, Y.; Li, B.; Gong, G. X.; Schuchman, E. H. Deregulation of sphingolipid metabolism in Alzheimer's disease Neurobiol. Aging 2010, 31 (3) 398-408
51. Rodriguez-Crespo, I. d -Amino acids in the brain: pyridoxal phosphate-dependent amino acid racemases and the physiology of d -serine FEBS J. 2008, 275 (14) 3513
52. Suh, Y. H.; Checler, F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease Pharmacol. Rev. 2002, 54 (3) 469-525
53. Wolosker, H.; Dumin, E.; Balan, L.; Foltyn, V. N. d -Amino acids in the brain: d -serine in neurotransmission and neurodegeneration FEBS J. 2008, 275 (14) 3514-26
54. Mothet, J. P.; Parent, A. T.; Wolosker, H.; Brady, R. O., Jr.; Linden, D. J.; Ferris, C. D.; Rogawski, M. A.; Snyder, S. H. d -serine is an endogenous ligand for the glycine site of the N -methyl- d -aspartate receptor Proc. Natl. Acad. Sci. U. S. A. 2000, 97 (9) 4926-31
55. Hashimoto, K.; Fukushima, T.; Shimizu, E.; Okada, S.; Komatsu, N.; Okamura, N.; Koike, K.; Koizumi, H.; Kumakiri, C.; Imai, K.; Iyo, M. Possible role of d -serine in the pathophysiology of Alzheimer's disease. Prog Neuropsychopharmacol. Biol. Psychiatry 2004, 28 (2) 385-8
56. Brito-Moreira, J.; C. Paula-Lima, A.; R. Bomfim, T.; F. Oliveira, F.; J. Sepulveda, F.; G. De Mello, F.; G. Aguayo, L.; Panizzutti, R.; T. Ferreira, S. Abeta oligomers induce glutamate release from hippocampal neurons Curr. Alzheimer Res. 2011, 8 (5) 552-62
57. Wu, S. Z.; Basile, A. S.; Barger, S. W. Induction of serine racemase expression and d -serine release from microglia by secreted amyloid precursor protein (sAPP) Curr. Alzheimer Res. 2007, 4 (3) 243-51
58. Wu, S. Z.; Bodles, A. M.; Porter, M. M.; T Griffin, W. S.; Basile, A. S.; Barger, S. W. Induction of serine racemase expression and d -serine release from microglia by amyloid beta-peptide J. Neuroinflammation 2004, 10.1186/1742-2094-1-2
59. Smith, C. D.; Wekstein, D. R.; Markesbery, W. R.; Frye, C. A. 3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia Psychopharmacology 2006, 186 (3) 481-5
60. Kim, S. B.; Kim, M.; Kwak, Y. T.; Hampl, R.; Jo, D. H.; Morfin, R. Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics J. Clin. Endocrinol. Metab. 2003, 88 (11) 5199-206
61. Attal-Khemis, S.; Dalmeyda, V.; Michot, J. L.; Roudier, M.; Morfin, R. Increased total 7 alpha-hydroxy-dehydroepiandrosterone in serum of patients with Alzheimer's disease J. Gerontol., Ser. A 1998, 53 (2) B125-32
62. Rasmuson, S.; Nasman, B.; Carlstrom, K.; Olsson, T. Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer's disease Dementia Geriatr. Cognit. Disord. 2002, 13 (2) 74-9
63. Baulieu, E. E.; Robel, P.; Schumacher, M. Neurosteroids: beginning of the story Int. Rev. Neurobiol. 2001, 46, 1-32
64. Montine, T. J.; Morrow, J. D. Fatty acid oxidation in the pathogenesis of Alzheimer's disease Am. J. Pathol. 2005, 166 (5) 1283-9
65. Lee, M. J.; Park, S. H.; Han, J. H.; Hong, Y. K.; Hwang, S.; Lee, S.; Kim, D.; Han, S. Y.; Kim, E. S.; Cho, K. S. The effects of hempseed meal intake and linoleic acid on Drosophila models of neurodegenerative diseases and hypercholesterolemia Mol. Cells 2011, 31 (4) 337-42
66. Wilson, D. M.; Binder, L. I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease Am. J. Pathol. 1997, 150 (6) 2181-95
67. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 2006, 12 (9) 1005-15
68. Srinivasan, B. D.; Kulkarni, P. S. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation Prog. Clin. Biol. Res. 1989, 312, 229-49
69. Burke, J. E.; Dennis, E. A. Phospholipase A2 structure/function, mechanism, and signaling J. Lipid Res. 2009, 50 (Suppl) S237-42
70. Stephenson, D.; Rash, K.; Smalstig, B.; Roberts, E.; Johnstone, E.; Sharp, J.; Panetta, J.; Little, S.; Kramer, R.; Clemens, J. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration Glia 1999, 27 (2) 110-28
71. Sanchez-Mejia, R. O.; Newman, J. W.; Toh, S.; Yu, G. Q.; Zhou, Y.; Halabisky, B.; Cissé, M.; Scearce-Levie, K.; Cheng, I. H.; Gan, L.; Palop, J. J.; Bonventre, J. V.; Mucke, L. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease Nat. Neurosci. 2008, 11 (11) 1311-8
72. Lipton, P. Ischemic cell death in brain neurons Phys. Rev. 1999, 79 (4) 1431-568
73. Sanchez-Mejia, R. O.; Mucke, L. Phospholipase A2 and arachidonic acid in Alzheimer's disease Biochim. Biophys. Acta 2010, 1801 (8) 784-90
74. Coîté, S.; Carmichael, P. H.; Verreault, R.; Lindsay, J.; Lefebvre, J.; Laurin, D. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease Alzheimer's Dementia 2012, 8 (3) 219-26
75. Coma, M.; Serenó, L.; Da Rocha-Souto, B.; Scotton, T. C.; España, J.; Sánchez, M. B.; Rodríguez, M.; Agulló, J.; Guardia-Laguarta, C.; Garcia-Alloza, M.; Borrelli, L. A.; Clarimón, J.; Lleó, A.; Bacskai, B. J.; Saura, C. A.; Hyman, B. T.; Gómez-Isla, T. Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease Neurobiol. Dis. 2010, 38 (3) 482-91
76. Esposito, G.; Giovacchini, G.; Liow, J. S.; Bhattacharjee, A. K.; Greenstein, D.; Schapiro, M.; Hallett, M.; Herscovitch, P.; Eckelman, W. C.; Carson, R. E.; Rapoport, S. I. Imaging neuroinflammation in Alzheimer disease with radiolabeled arachidonic acid and PET J. Nucl. Med. 2008, 49 (9) 1414-21
77. McGeer, P. L.; McGeer, E. G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies Neurobiol. Aging 2007, 28 (5) 639-47
78. OresI, M.; Hyötyläinen, T.; Herukka, S.-K.; Sysi-Aho, M.; Mattila, I.; Seppänan-Laakso, T.; Julkunen, V.; Gopalacharyulu, P. V.; Hallikainen, M.; Koikkalainen, J.; Kivipelto, M.; Helisalmi, S.; Lötjönen, J.; Soininen, H. Metabolome in progression to Alzheimer's disease Transl. Psychiatry 2011, 1, e57
79. Ferrer, I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease J. Bioenerg. Biomembr. 2009, 41 (5) 425-31
80. Ogawa, M.; Fukuyama, H.; Ouchi, Y.; Yamauchi, H.; Kimura, J. Altered energy metabolism in Alzheimer's disease J. Neurol. Sci. 1996, 139 (1) 78-82
81. Atamna, H.; Frey, W. H., 2nd. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease Mitochondrion 2007, 7 (5) 297-310
82. Blass, J. P.; Sheu, R. K.; Gibson, G. E. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise Ann. N. Y. Acad. Sci. 2000, 903, 204-21
83. Beal, M. F. Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment Neurobiol. Aging 2005, 26 (5) 585-6
84. Sun, J.; Feng, X.; Liang, D.; Duan, Y.; Lei, H. Down-regulation of energy metabolism in Alzheimer's disease is a protective response of neurons to the microenvironment J. Alzheimer's Dis. 2012, 28 (2) 389-402